{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T05:10:17Z","timestamp":1685855417268},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1007\/s00393-010-0640-2","type":"journal-article","created":{"date-parts":[[2010,11,9]],"date-time":"2010-11-09T18:57:24Z","timestamp":1289329044000},"page":"780-787","source":"Crossref","is-referenced-by-count":12,"title":["Biologika in Schwangerschaft und Stillzeit","Biologics during pregnancy and breast-feeding"],"prefix":"10.1007","volume":"69","author":[{"given":"R.E.","family":"Fischer-Betz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,11,7]]},"reference":[{"key":"640_CR1","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1095\/biolreprod54.3.554","volume":"54","author":"Hunt","year":"1996","unstructured":"Hunt JS, Chen HL, Miller L (1996) Tumor necrosis factors: pivotal components of pregnancy? Biol Reprod 54:554\u2013562","journal-title":"Biol Reprod"},{"key":"640_CR2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1023\/A:1021740108284","volume":"20","author":"Toder","year":"2003","unstructured":"Toder V, Fein A, Carp H, Torchinsky A (2003) TNF-alpha in pregnancy loss and embryo maldevelopment: a mediator of detrimental stimuli or a protector of the fetoplacental unit? J Assist Reprod Genet 20:73\u201381","journal-title":"J Assist Reprod Genet"},{"key":"640_CR3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.4049\/jimmunol.174.1.485","volume":"174","author":"Berman","year":"2005","unstructured":"Berman J, Girardi G, Salmon JE (2005) TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 174:485\u2013490","journal-title":"J Immunol"},{"key":"640_CR4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-0897.2008.00585.x","volume":"60","author":"Winger","year":"2008","unstructured":"Winger EE, Reed JL (2008) Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion. Am J Reprod Immunol 60:8\u201316","journal-title":"Am J Reprod Immunol"},{"key":"640_CR5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1600-0897.2008.00669.x","volume":"61","author":"Winger","year":"2009","unstructured":"Winger EE, Reed JL, Ashoush S et al (2009) Treatment with adalimumab (Humira) and intravenous immunoglobulin improves pregnancy rates in women undergoing IVF. Am J Reprod Immunol 61:113\u2013120","journal-title":"Am J Reprod Immunol"},{"key":"640_CR6","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1191\/096032700678815765","volume":"19","author":"Treacy","year":"2000","unstructured":"Treacy G (2000) Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFalpha monoclonal antibody. Hum Exp Toxicol 19:226\u2013228","journal-title":"Hum Exp Toxicol"},{"key":"640_CR7","unstructured":"Briggs GG (2005) Drugs in pregnancy and lactation. 7.Aufl. Williams & Wilkins, Baltimore"},{"key":"640_CR8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/10915810802368196","volume":"27","author":"Martin","year":"2008","unstructured":"Martin PL, Cornacoff JB, Treacy G et al (2008) Effects of administration of a monoclonal antibody against mouse tumor necrosis factor alpha during pregnancy and lactation on the pre- and postnatal development of the mouse immune system. Int J Toxicol 27:341\u2013347","journal-title":"Int J Toxicol"},{"key":"640_CR9","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.cgh.2006.07.018","volume":"4","author":"Vasiliauskas","year":"2006","unstructured":"Vasiliauskas EA, Church JA, Silverman N et al (2006) Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 4:1255\u20131258","journal-title":"Clin Gastroenterol Hepatol"},{"key":"640_CR10","unstructured":"Mahadevan U, Terdiman JP, Church J et al (2007) Infliximab levels in infants born to women with inflammatory bowel disease. Dig Dis Week, abstract 959"},{"key":"640_CR11","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1136\/ard.2008.105924","volume":"68","author":"Murashima","year":"2009","unstructured":"Murashima A, Watanabe N, Ozawa N et al (2009) Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant\u2019s serum. Ann Rheum Dis 68:1793\u20131794","journal-title":"Ann Rheum Dis"},{"key":"640_CR12","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/ard.2008.105254","volume":"69","author":"Porter","year":"2010","unstructured":"Porter C, Kopotsha T, Smith B et al (2010) No significant transfer of certolizumab pegol compared with IgG in the perfused human placenta in vitro. Ann Rheum Dis 69 (Suppl3):210","journal-title":"Ann Rheum Dis"},{"key":"640_CR13","doi-asserted-by":"crossref","unstructured":"Nesbitt ABD, Stephens S, Foulkes R (2006) Placental transfer and accumulation in milk of the anti TNF-antibody TN3 in rats: immunoglobulin G1 versus PEGylated FAB. Am J Gastroenterol, abstract 119","DOI":"10.14309\/00000434-200609001-01119"},{"key":"640_CR14","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1136\/gut.2008.166884","volume":"58","author":"Oussalah","year":"2009","unstructured":"Oussalah A, Bigard MA, Peyrin-Biroulet L (2009) Certolizumab in pregnancy. Gut 58:608","journal-title":"Gut"},{"key":"640_CR15","doi-asserted-by":"crossref","first-page":"iv18","DOI":"10.1136\/ard.2005.042549","volume":"64","author":"Cush","year":"2005","unstructured":"Cush JJ (2005) Biological drug use: US perspectives on indications and monitoring. Ann Rheum Dis 64:iv18\u201323","journal-title":"Ann Rheum Dis"},{"key":"640_CR16","doi-asserted-by":"crossref","unstructured":"Ostensen M, Lockshin M, Doria A et al (2008) Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology (Oxford) 47:iii28","DOI":"10.1093\/rheumatology\/ken168"},{"key":"640_CR17","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/art.24462","volume":"61","author":"Vinet","year":"2009","unstructured":"Vinet E, Pineau C, Gordon C et al (2009) Biologic therapy and pregnancy outcomes in women with rheumatic diseases. Arthritis Rheum 61:587\u2013592","journal-title":"Arthritis Rheum"},{"key":"640_CR18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3899\/jrheum.090563","volume":"37","author":"Ali","year":"2010","unstructured":"Ali YM, Kuriya B, Orozco C et al (2010) Can tumor necrosis factor inhibitors be safely used in pregnancy? J Rheumatol 37:9\u201317","journal-title":"J Rheumatol"},{"key":"640_CR19","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1111\/j.1572-0241.2004.30186.x","volume":"99","author":"Katz","year":"2004","unstructured":"Katz JA, Antoni C, Keenan GF et al (2004) Outcome of pregnancy in women receiving infliximab for the treatment of Crohn\u2019s disease and rheumatoid arthritis. Am J Gastroenterol 99:2385\u20132392","journal-title":"Am J Gastroenterol"},{"key":"640_CR20","first-page":"122","volume":"68","author":"Snoeckx","year":"2009","unstructured":"Snoeckx Y, Keenan G, Sanders M, Gardiner M (2009) Update on pregnancy outcomes in women taking Infliximab: the Infliximab safety database. Ann Rheum Dis 68 (Suppl 3):122","journal-title":"Ann Rheum Dis"},{"key":"640_CR21","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1002\/art.22028","volume":"54","author":"Hyrich","year":"2006","unstructured":"Hyrich K, Watson K, Dixon W et al (2006) Pregnancy experience in women with rheumatic diseases exposed to biologic agents: results from the BSR biologic register. Arthritis Rheum 54:2701\u20132702","journal-title":"Arthritis Rheum"},{"key":"640_CR22","first-page":"S542","volume":"Rheum","author":"King","year":"2008","unstructured":"King Y, Watson KD, Symmons DPM et al (2008) Pregnancy outcome in women exposed to Anti-TNF Agents: An update from the British Society for Rheumatoogy Biologics Register. Arthritis Rheum (Suppl 58):S542 (abstract)","journal-title":"Arthritis"},{"key":"640_CR23","first-page":"317","volume":"65","author":"Garcia-Gonzalez","year":"2006","unstructured":"Garcia-Gonzalez A, Joven B, Ruiz T et al (2006) Pregnancy in women receiving anti TNF-alpha therapy: experience in Spain. Ann Rheum Dis 65:317 (abstract)","journal-title":"Ann Rheum Dis"},{"key":"640_CR24","unstructured":"Strangfeld A, Listing J, Rau R et al (2007) Pregnancy outcome after exposure to biologics: Results from the German Biologics Register RABBIT. ACR 2007 No. 730 (abstract)"},{"key":"640_CR25","doi-asserted-by":"crossref","unstructured":"Johnson DL, Jones KL, Jimenez J et al (2009) Pregnancy outcomes in women exposed to adalimumab: An update on the autoimmune diseases in pregnancy uroject. http:\/\/www.otispregnancy.org\/hm\/download.php?id=12&client_id","DOI":"10.14309\/00000434-200910003-01114"},{"key":"640_CR26","doi-asserted-by":"crossref","unstructured":"Johnson DL, Jones KL, Chambers CD (2008) Pregnancy outcomes in women exposed to etanercept. The OTIS autoimmune disease in pregnancy project. http:\/\/www.otispregnancy.org\/hm\/download.php?id=12&client_id)","DOI":"10.14309\/00000434-200809001-00958"},{"key":"640_CR27","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2036.2005.02405.x","volume":"21","author":"Mahadevan","year":"2005","unstructured":"Mahadevan U, Kane S, Sandborn WJ et al (2005) Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn\u2019s disease. Aliment Pharmacol Ther 21:733\u2013738","journal-title":"Aliment Pharmacol Ther"},{"key":"640_CR28","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.dld.2006.01.017","volume":"8","author":"Tursi","year":"2006","unstructured":"Tursi A (2006) Effect of intentional infliximab use throughout pregnancy in inducing and maintaining remission in Crohn\u2019s disease. Dig Liver Dis 8:439\u2013440","journal-title":"Dig Liver Dis"},{"key":"640_CR29","unstructured":"Schnitzler F, Fidder HH, Ferrante M et al (2007) Intentional treatment with infliximab during pregnancy in women with inflammatory bowel disease. Dig Dis Week, abstract 958"},{"key":"640_CR30","doi-asserted-by":"crossref","unstructured":"Rosner I, Haddad A, Boulman N et al (2007) Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford) 46:1508","DOI":"10.1093\/rheumatology\/kem068"},{"key":"640_CR31","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/gut.2005.065417","volume":"54","author":"Vesga","year":"2005","unstructured":"Vesga L, Terdiman JP, Mahadevan U (2005) Adalimumab use in pregnancy. Gut 54:890","journal-title":"Gut"},{"key":"640_CR32","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1007\/s10620-006-9452-2","volume":"51","author":"Coburn","year":"2006","unstructured":"Coburn LA, Wise PE, Schwartz DA (2006) The successful use of adalimumab to treat active Crohn\u2019s disease of an ileoanal pouch during pregnancy. Dig Dis Sci 51:2045\u20132047","journal-title":"Dig Dis Sci"},{"key":"640_CR33","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/00054725-200608000-00020","volume":"12","author":"Mishkin","year":"2006","unstructured":"Mishkin DS, Van Deinse W, Becker JM, Farraye FA (2006) Successful use of adalimumab (Humira) for Crohn\u2019s disease in pregnancy. Inflamm Bowel Dis 12:827\u2013828","journal-title":"Inflamm Bowel Dis"},{"key":"640_CR34","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jbspin.2008.04.016","volume":"76","author":"Berthelot","year":"2009","unstructured":"Berthelot JM, De Bandt M, Goupille P et al (2009) Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine 76:28\u201334","journal-title":"Joint Bone Spine"},{"key":"640_CR35","doi-asserted-by":"crossref","unstructured":"Rump JA, Sch\u00f6nborn H (2010) Conception and course of eight pregnancies in five women on TNF blocker etanercept treatment. Z Rheumatol [Epub ahead of print Jun 9]","DOI":"10.1007\/s00393-010-0652-y"},{"key":"640_CR36","first-page":"1014","volume":"33","author":"Carter","year":"2006","unstructured":"Carter JD, Valeriano J, Vasey FB (2006) Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship. J Rheumatol 33:1014\u20131017","journal-title":"J Rheumatol"},{"key":"640_CR37","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3899\/jrheum.080545","volume":"36","author":"Carter","year":"2009","unstructured":"Carter JD, Ladhani A, Ricca LR et al (2009) A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 36:635\u2013641","journal-title":"J Rheumatol"},{"key":"640_CR38","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","volume":"91","author":"Amato","year":"1994","unstructured":"Amato RJ de, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91:4082\u20134085","journal-title":"Proc Natl Acad Sci U S A"},{"key":"640_CR39","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/ard.2004.029538","volume":"64","author":"\u00d8stensen","year":"2005","unstructured":"\u00d8stensen M, F\u00f6rger F, Nelson JL et al (2005) Pregnancy in patients with rheumatic disease: anti-inflammatory cytokines increase in pregnancy and decrease post partum. Ann Rheum Dis 64:839\u2013844","journal-title":"Ann Rheum Dis"},{"key":"640_CR40","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1191\/0961203304lu485oa","volume":"13","author":"F\u00f6rger","year":"2004","unstructured":"F\u00f6rger F, Matthias T, Oppermann M et al (2004) Infliximab in breast milk. Lupus 13:753","journal-title":"Lupus"},{"key":"640_CR41","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/MCG.0b013e31817f9367","volume":"43","author":"Kane","year":"2009","unstructured":"Kane S, Ford J, Cohen R, Wagner C (2009) Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn\u2019s disease before and after delivery. J Clin Gastroenterol 43:613\u2013616","journal-title":"J Clin Gastroenterol"},{"key":"640_CR42","first-page":"1017","volume":"31","author":"Ostensen","year":"2004","unstructured":"Ostensen M, Eigenmann GO (2004) Etanercept in breast milk. J Rheumatol 31:1017\u20131018","journal-title":"J Rheumatol"},{"key":"640_CR43","doi-asserted-by":"crossref","unstructured":"Berthelsen B, Nielsen HF, Nielsen CT, Hellmuth E (2010) Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. Rheumatology (Oxford) [Epub ahead of print]","DOI":"10.1093\/rheumatology\/keq185"},{"key":"640_CR44","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cgh.2009.11.023","volume":"8","author":"Ben-Horin","year":"2010","unstructured":"Ben-Horin S, Yavzori M, Katz L et al (2010) Adalimumab Level in Breast Milk of a Nursing Mother. Clin Gastroenterol Hepatol 8:475\u2013476","journal-title":"Clin Gastroenterol Hepatol"},{"key":"640_CR45","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3899\/jrheum.080554","volume":"36","author":"Paschou","year":"2009","unstructured":"Paschou S, Voulgari PV, Vrabie IG et al (2009) Fertility and reproduction in male patients with ankylosing spondylitis treated with infliximab. J Rheumatol 36:351\u2013354","journal-title":"J Rheumatol"},{"key":"640_CR46","unstructured":"Barcelo M, Sellas A, Rodr\u00edguez-Diez B et al (2009) Paternity in patients treated with Anti-TNF therapy. ACR 2009 [SAT0279]"},{"key":"640_CR47","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1530\/eje.0.1510629","volume":"151","author":"Suominen","year":"2004","unstructured":"Suominen JS, Wang Y, Kaipia A, Toppari J (2004) Tumor necrosis factor-alpha (TNF-alpha) promotes cell survival during spermatogenesis, and this effect can be blocked by infliximab, a TNF-alpha antagonist. Eur J Endocrinol 151:629\u2013640","journal-title":"Eur J Endocrinol"},{"key":"640_CR48","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/j.fertnstert.2004.11.068","volume":"83","author":"Said","year":"2005","unstructured":"Said TM, Agarwal A, Falcone T et al (2005) Infliximab may reverse the toxic effects induced by tumor necrosis factor alpha in human spermatozoa: an in vitro model. Fertil Steril 83:1665\u20131673","journal-title":"Fertil Steril"},{"key":"640_CR49","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1136\/ard.2005.038620","volume":"64","author":"La","year":"2005","unstructured":"La Montagna GL, Malesci D, Buono R, Valentini G (2005) Asthenoazoospermia in patients receiving anti-tumour necrosis factor {alpha} agents. Ann Rheum Dis 64:1667","journal-title":"Ann Rheum Dis"},{"key":"640_CR50","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1136\/ard.2009.127423","volume":"69","author":"Villiger","year":"2010","unstructured":"Villiger PM, Caliezi G, Cottin V et al (2010) Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis. Ann Rheum Dis 69:1842\u20131844","journal-title":"Ann Rheum Dis"},{"key":"640_CR51","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.ajog.2006.09.002","volume":"195","author":"Murtha","year":"2006","unstructured":"Murtha AP, Nieves A, Hauser ER et al (2006) Association of maternal IL-1 receptor antagonist intron 2 gene polymorphism and preterm birth. Am J Obstet Gynecol 195:1249\u20131253","journal-title":"Am J Obstet Gynecol"},{"key":"640_CR52","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.ajog.2006.06.072","volume":"195","author":"Sadowsky","year":"2006","unstructured":"Sadowsky DW, Adams KM, Gravett MG et al (2006) Preterm labor is induced by intraamniotic infusions or interleukin-1beta and tumor necrosis factor-alpha but not by interleukin-6 or interleukin-8 in a nonhumate primate model. Am J Obstet Gynecol 195:1578\u20131589","journal-title":"Am J Obstet Gynecol"},{"key":"640_CR53","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1136\/ard.2008.105833","volume":"68","author":"Berger","year":"2009","unstructured":"Berger CT, Recher M, Steiner U, Hauser TM (2009) A patients wish: anakinra in pregnancy. Ann Rheum Dis 68:1794\u20131795","journal-title":"Ann Rheum Dis"},{"key":"640_CR54","first-page":"678","volume":"69","author":"Bazzani","year":"2010","unstructured":"Bazzani C, Ramoni V, Scrivo R et al (2010) Pregnancy outcomes in women exposed to biologic treatment and affected by chronic arthritis. Ann Rheum Dis 69 (Suppl 3):678","journal-title":"Ann Rheum Dis"},{"key":"640_CR55","unstructured":"(o A) (2007) Fachinformation Orencia Bristol-Myers Squibb"},{"key":"640_CR56","doi-asserted-by":"crossref","unstructured":"\u00d8stensen M, Lockshin M, Doria A et al (2008) Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology (Oxford) 47(Suppl 3):iii28\u201331","DOI":"10.1093\/rheumatology\/ken168"},{"key":"640_CR57","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1136\/ard.2008.099184","volume":"69","author":"Ishikawa","year":"2010","unstructured":"Ishikawa H, Kanamono T, Kojima T et al (2010) Treatment of young female patients with rheumatoid arthritis using biological agents- results from 6 years of clinical practice in Japanese TBC registry for the patients with rheumatoid arthritis using biologics. Ann Rheum Dis 69 (Suppl):679","journal-title":"Ann Rheum Dis"},{"key":"640_CR58","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1600-0609.2004.00214.x","volume":"72","author":"Kimby","year":"2004","unstructured":"Kimby E, Sverrisdottir A, Elinder G (2004) Safety of rituximab therapy during the first trimester of pregnancy: a case history. Eur J Haematol 72:292\u2013295","journal-title":"Eur J Haematol"},{"key":"640_CR59","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1470-2045(06)70797-5","volume":"7","author":"Decker","year":"2006","unstructured":"Decker M, Rothermundt C, Holl\u00e4nder G et al (2006) Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. Lancet Oncol 7:693\u2013694","journal-title":"Lancet Oncol"},{"key":"640_CR60","unstructured":"Friedrichs B, Tiemann M, Salwender H et al (2006) The effects of rituximab treatment during pregnancy on a neonate, Haematologica 91:1426\u20131427"},{"key":"640_CR61","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/01.mbc.0000240918.65306.20","volume":"17","author":"Scully","year":"2006","unstructured":"Scully M, Starke R, Lee R et al (2006) Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura. Blood Coagul Fibrinolysis 17:459\u2013463","journal-title":"Blood Coagul Fibrinolysis"},{"key":"640_CR62","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/sj.jp.7211481","volume":"26","author":"Ojeda-Uribe","year":"2006","unstructured":"Ojeda-Uribe M, Gilliot C, Jung G et al (2006) Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. J Perinatol 26:252\u2013255","journal-title":"J Perinatol"},{"key":"640_CR63","first-page":"1363","volume":"27","author":"Klink","year":"2008","unstructured":"Klink DT, Elburg RM van, Schreurs MW, Well GT van (2008) Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol 27:1363","journal-title":"Clin Dev Immunol"},{"key":"640_CR64","unstructured":"Diaz MC, Gutierrez JJM, Buitrago VV (2008) Rituximab and pregnancy: Case report. EULAR 0448"},{"key":"640_CR65","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1177\/1352458509106512","volume":"15","author":"Pellkofer","year":"2009","unstructured":"Pellkofer HL, Suessmair C, Schulze A et al (2009) Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab. Mult Scler 15:1006\u20131008","journal-title":"Mult Scler"},{"key":"640_CR66","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/j.leukres.2008.04.004","volume":"33","author":"Rey","year":"2009","unstructured":"Rey J, Coso D, Roger V et al (2009) Rituximab combined with chemotherapy for lymphoma during pregnancy. Leuk Res 33:e8\u2013e9","journal-title":"Leuk Res"},{"key":"640_CR67","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jaad.2009.05.015","volume":"63","author":"Ponte","year":"2010","unstructured":"Ponte P, Lopes MJ (2010) Apparent safe use of single dose rituximab for recalcitrant atopic dermatitis in the first trimester of a twin pregnancy. J Am Acad Dermatol 63:355\u2013356","journal-title":"J Am Acad Dermatol"},{"key":"640_CR68","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1200\/JCO.2001.19.14.3439","volume":"19","author":"Herold","year":"2001","unstructured":"Herold M, Schnohr S, Bittrich H (2001) Efficacy and safety of a combined rituximab chemotherapy during pregnancy. J Clin Oncol 19:3439","journal-title":"J Clin Oncol"},{"key":"640_CR69","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/01.AOG.0000189719.36625.8f","volume":"108","author":"Magloire","year":"2006","unstructured":"Magloire LK, Pettker CM, Buhimschi CS, Funai EF (2006) Burkitt\u2019s lymphoma of the ovary in pregnancy. Obstet Gynecol 108:743\u2013745","journal-title":"Obstet Gynecol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-010-0640-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-010-0640-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-010-0640-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T04:48:08Z","timestamp":1685854088000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-010-0640-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":69,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["640"],"URL":"https:\/\/doi.org\/10.1007\/s00393-010-0640-2","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}